Provide feedbackProvide feedback

Home :: Rheumatology :: Rheumatology Conferences :: EULAR 2007 Annual Congress

European League Against Rheumatism

EULAR 2007 Annual Congress

June 13-16, 2007Barcelona, Spain
VerusMed is an independent news organization and is not affiliated with the European League Against Rheumatism

Continued infliximab improves, maintains 1-year physical function in patients with PsA

Monday, June 18, 2007 | Comments

Infliximab improves physical function in patients with psoriatic arthritis, regardless of baseline radiographic damage, and maintains improved functional status through 54 weeks of treatment, IMPACT 2 results indicate.

Trial participants had active PsA, no prior anti-tumor necrosis factor therapy, and no disease-modifying ...[more] Locked

Patients with RA, PsA, AS who have not responded to etanercept, infliximab show response to adalimumab, according to subanalyses

Friday, June 15, 2007 | Comments

Adalimumab is an effective and safe treatment in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who have not responded adequately to prior treatment with etanercept or infliximab, study results indicate.

Dr. Gerd Burmester, lead author of the study, noted that subjects were involved in ...[more] Locked

Biologics represent useful treatment for PsA; other therapies, approaches require more study

Monday, June 18, 2007 | Comments

Good clinical data support the use of biologic drugs in psoriatic arthritis, but more research is necessary to find additional treatments and appropriate therapeutic methods to treat this condition, presenters said.

Douglas Veale, a professor at the University College Dublin, spoke about ...[more] Locked

Leflunomide improves symptoms of dactylitis, fatigue, skin disease among patients with PsA, researchers report

Monday, June 18, 2007 | Comments

Leflunomide is effective and well tolerated in the treatment of psoriatic arthritis in daily clinical practice, with benefits in dactylitis, fatigue, and skin disease, according to study findings.

"We've heard a lot of data on the anti-TNF [agents]; we have excellent evidence for these drugs, but these are second-line," ...[more] Locked

Certolizumab pegol improves signs, symptoms of RA among patients with insufficient response to methotrexate, study data show

Friday, June 15, 2007 | Comments

The addition of certolizumab pegol to methotrexate reduces the signs and symptoms of active rheumatoid arthritis among patients who have had an insufficient response to methotrexate monotherapy, according to preliminary data from a recent study.

Certolizumab is a humanized, pegylated Fab fragment that targets tumor ...[more] Locked

Anti-TNF agents improve signs, symptoms of AS without preventing progression of radiographic damage; many questions remain unanswered, according to panel of experts

Tuesday, June 19, 2007 | Comments

Mounting evidence confirms that treatment of ankylosing spondylitis using anti-tumor necrosis factor agents reduces signs and symptoms of AS but does not prevent progression of radiographic damage, according to a panel of experts.

Dr. Desiree van der Heijde of Leiden ...[more] Locked

Adalimumab safe, effective in anti-TNF-pretreated patients with PsA, study data show

Monday, June 18, 2007 | Comments

Adalimumab appears effective and well tolerated in the treatment of patients with psoriatic arthritis, providing improvements in both skin disease and arthropathy, according to findings from the STEREO trial.

In the open-label prospective trial, 442 patients with active PsA and insufficient response to at least 1 ...[more] Locked

Etanercept remains efficacious for up to 212 weeks in AS

Tuesday, June 19, 2007 | Comments

Among individuals with ankylosing spondylitis, etanercept sustains improvements in clinical efficacy and quality-of-life indicators after 4 years of treatment, according to data from an ongoing open-label Phase IV extension study.

Initially, participants were randomized to receive 25 mg of subcutaneous etanercept (n=45) ...[more] Locked

Anti-TNF agents may slow, protect against RA-related joint destruction, disability, work loss

Saturday, June 16, 2007 | Comments

Rheumatoid arthritis can lead to joint destruction, disability, and job loss, but anti-tumor necrosis factor therapies have shown their ability to slow or even prevent these outcomes, according to 2 rheumatology experts.

Dr. Josef Smolen, chairman of the rheumatology department at ...[more] Locked

Repair of joint erosions in patients with RA occurs primarily in joints with no swelling, improvement in swelling, researchers report

Friday, June 15, 2007 | Comments

Repair of joint erosions among patients with rheumatoid arthritis appears to occur almost exclusively in joints without swelling or in those that show improvement in swelling, whereas progression occurs in joints with persistent swelling, according to a post hoc analysis of preliminary data from the TEMPO study.

In the ...[more] Locked

Adalimumab's efficacy in AS maintained after long-term treatment, data indicate

Tuesday, June 19, 2007 | Comments

Adalimumab reduces the signs and symptoms of ankylosing spondylitis, with results maintained after >=2 years of treatment, according to data from the ATLAS trial.

The trial included adults with active AS who had shown an inadequate response to >=1 nonsteroidal antiinflammatory drug. Participants were randomized to receive ...[more] Locked

  1. No articles have been read
  1. No articles have been emailed